New Rochelle, NY, June 23, 2016 -Replacing dopamine-producing cells in the brain represents a promising therapeutic approach in Parkinson's disease, and a new study shows how post-transplantation gamma-ray irradiation can reduce the risk of tumor formation. The study, in which human induced pluripotent stem (iPS) cell-derived neural progenitor cells were grafted into rat brains, is published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Stem Cells and Development website until July 23, 2016.
Mitsuko Katsukawa and coauthors from Kyoto University and Kyoto University Graduate School of Medicine, Japan, describe the fail-safe strategy they developed to prevent immature or undifferentiated cells in the therapeutic graft from forming tumors, while allowing the desired cells to survive. These results will contribute to improved safety of cell replacement therapy using human iPS cells for Parkinson's disease, conclude the researchers in the article "Fail-Safe Therapy by Gamma-Ray Irradiation Against Tumor Formation by Human-Induced Pluripotent Stem Cell-Derived Neural Progenitors".
"While the world waits with bated breath to see whether the use of iPS cells in humans will proceed safely, this is the first attempt to use radiation to mitigate the risk of tumor formation after stem cell transplantation," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.